TN2010000155A1 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
TN2010000155A1
TN2010000155A1 TN2010000155A TN2010000155A TN2010000155A1 TN 2010000155 A1 TN2010000155 A1 TN 2010000155A1 TN 2010000155 A TN2010000155 A TN 2010000155A TN 2010000155 A TN2010000155 A TN 2010000155A TN 2010000155 A1 TN2010000155 A1 TN 2010000155A1
Authority
TN
Tunisia
Prior art keywords
organic compounds
modulator
parkinson
progression
disease
Prior art date
Application number
TN2010000155A
Other languages
English (en)
Inventor
Daniel Umbricht
Mancilla Baltazar Gomez
Fabrizio Gasparini
Paolo Therese Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2010000155A1 publication Critical patent/TN2010000155A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
TN2010000155A 2007-10-12 2010-04-12 Organic compounds TN2010000155A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97948607P 2007-10-12 2007-10-12
US5033308P 2008-05-05 2008-05-05
PCT/EP2008/063544 WO2009047296A2 (fr) 2007-10-12 2008-10-09 Composés organiques

Publications (1)

Publication Number Publication Date
TN2010000155A1 true TN2010000155A1 (en) 2011-11-11

Family

ID=40348021

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2010000155A TN2010000155A1 (en) 2007-10-12 2010-04-12 Organic compounds

Country Status (19)

Country Link
US (2) US20100249136A1 (fr)
EP (1) EP2211859B1 (fr)
JP (2) JP5743545B2 (fr)
KR (1) KR101572280B1 (fr)
CN (1) CN101854935A (fr)
AU (1) AU2008309621A1 (fr)
BR (1) BRPI0818560A2 (fr)
CA (1) CA2701853A1 (fr)
CL (1) CL2008003006A1 (fr)
IL (1) IL204954A0 (fr)
MA (1) MA31798B1 (fr)
MX (1) MX2010003913A (fr)
NZ (1) NZ584856A (fr)
RU (1) RU2508107C2 (fr)
SG (1) SG185293A1 (fr)
TN (1) TN2010000155A1 (fr)
TW (1) TW200924745A (fr)
WO (1) WO2009047296A2 (fr)
ZA (1) ZA201002423B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131503A (zh) 2008-06-30 2011-07-20 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品
NZ590753A (en) * 2008-08-12 2012-06-29 Novartis Ag Processes for the preparation of 4-oxo-octahydro-indole-1-carbocylic acid methyl ester and derivatives thereof
DK2477629T3 (en) * 2009-09-17 2016-08-22 Univ Vanderbilt SUBSTITUTED HETEROARYLAMIDANALOGER AS mGluR5 allosteric modulators NEGATIVE AND METHODS OF MAKING AND USE THEREOF
AU2012223720A1 (en) 2011-03-03 2013-09-26 Vanderbilt University 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
CA2830458A1 (fr) 2011-03-18 2012-09-27 Novartis Ag Combinaisons d'activateurs des recepteurs nicotiniques a l'acetylcholine alpha 7 et d'antagonistes des mglur5 destinees a etre utilisees dans la dyskinesie induite par la dopaminedans la maladie de parkinson
GB201204962D0 (en) 2012-03-21 2012-05-02 Addex Pharmaceuticals Sa Pharmaceutical combination products for parkinsons disease
EP3071568A1 (fr) 2013-11-19 2016-09-28 Vanderbilt University Composés imidazopyridine et triazolopyridine substitués utilisés comme modulateurs allostériques négatifs de mglur
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
KR101749675B1 (ko) * 2015-07-20 2017-06-26 동국대학교 산학협력단 멜라닌 응집 호르몬을 유효성분으로 포함하는 파킨슨병 치료 및 레보도파 부작용 억제용 약학 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
CN1361768A (zh) * 1999-06-02 2002-07-31 Nps药物有限公司 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
US7105548B2 (en) * 2001-12-18 2006-09-12 Merck & Co., Inc. Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
AU2003267087A1 (en) * 2002-09-13 2004-04-30 Merck & Co., Inc. Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
WO2004069146A2 (fr) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Derives d'amide l-dopa et utilisations de ceux-ci
JP2007506741A (ja) * 2003-09-23 2007-03-22 メルク　エンド　カムパニー　インコーポレーテッド 向代謝性グルタミン酸受容体のピラゾール系調節剤
EP1715867A4 (fr) * 2004-02-12 2009-04-15 Merck & Co Inc Amides bipyridyles en tant que modulateurs du r cepteur-5 metabotropique du glutamate
JP4767975B2 (ja) * 2005-03-04 2011-09-07 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ５アンタゴニストとしてのピリジン−２−カルボキサミド誘導体
GB0508318D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
TW200801005A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
RU2008129622A (ru) * 2005-12-20 2010-01-27 Новартис АГ (CH) Производные никотиновой кислоты в качестве модуляторов метаботропных глутаматных рецепторов
EP2272509A1 (fr) * 2006-09-11 2011-01-12 Novartis AG Nouvelles utilisations des récepteurs du glutamate métabotropique
CN102131503A (zh) * 2008-06-30 2011-07-20 诺瓦提斯公司 用于治疗帕金森病的包含mGluR调节剂的组合产品

Also Published As

Publication number Publication date
NZ584856A (en) 2012-12-21
US20150272929A1 (en) 2015-10-01
BRPI0818560A2 (pt) 2019-09-24
EP2211859A2 (fr) 2010-08-04
ZA201002423B (en) 2010-12-29
KR20100088136A (ko) 2010-08-06
MA31798B1 (fr) 2010-10-01
TW200924745A (en) 2009-06-16
CA2701853A1 (fr) 2009-04-16
KR101572280B1 (ko) 2015-11-26
MX2010003913A (es) 2010-04-27
IL204954A0 (en) 2010-11-30
AU2008309621A1 (en) 2009-04-16
CN101854935A (zh) 2010-10-06
SG185293A1 (en) 2012-11-29
US20100249136A1 (en) 2010-09-30
RU2010118454A (ru) 2011-11-20
RU2508107C2 (ru) 2014-02-27
CL2008003006A1 (es) 2009-05-08
EP2211859B1 (fr) 2016-01-06
JP2011500529A (ja) 2011-01-06
JP2014240425A (ja) 2014-12-25
WO2009047296A2 (fr) 2009-04-16
WO2009047296A3 (fr) 2009-08-20
JP5743545B2 (ja) 2015-07-01

Similar Documents

Publication Publication Date Title
TN2010000155A1 (en) Organic compounds
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2006119295A3 (fr) Compositions et methodes de traitement de maladies neurodegeneratives
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
MX2009013199A (es) Anticuerpos anti-notch1 nnr y sus metodos de uso.
MX2009013082A (es) Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
TNSN08400A1 (en) Organic compounds and their uses
NL1030418A1 (nl) Azabenzoxazolen voor de behandeling van CZS-stoornissen.
MX2009002684A (es) Derivados de acido nicotinico como moduladores de receptores de glutamato metabotropico.
UA95627C2 (ru) Аминотиазолы и их применение
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
MX2009009693A (es) Metodos para activar irs-1 y akt.
NL1032552C2 (nl) Imidazoolverbindingen voor de behandeling van neurologische stoornissen.
MX2010004463A (es) Compuestos de indolina.
WO2008085927A3 (fr) Procédés, compositions et kits destinés au traitement de la douleur
WO2007064997A3 (fr) Composes et procedes permettant d'inhiber l'apoptose
WO2008103431A3 (fr) Liposomes adni
TN2009000495A1 (en) Macrocycles and their uses